We're pleased that you plan to submit your article! Before starting your submission, please check that this journal's publishing policy is compatible with your and your co-authors' funding agreements. Taylor & Francis requires you to delay making an Accepted Manuscript version of your article available if you are not publishing Open Access.
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
![Publish Open Access Finland]({"type":"image" , "src" : "/sda/110396/JournalAd-OA-Agreements.gif"})
![Call for Papers.]({"type":"image" , "src" : "/sda/111134/JournalAdOASubmissionCAIC.jpg"})
Tumors aberrantly express tumor-associated antigens that can be specifically recognized by T-cells, thereby providing a scientific rationale for the design and clinical testing of immunotherapeutic strategies targeting these antigens. Multiple myeloma is a fatal hematologic malignancy. Here, we review techniques to discover new tumor-associated antigens in multiple myeloma and the latest immunotherapeutic strategies employed in this disease.
PDF download + Online access
Issue Purchase
Purchase access via tokens
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.
